Trial Profile
A Phase 2 Proof of Concept Study of PMX-60056 for the Reversal of Heparin in Patients Undergoing Percutaneous Coronary Intervention (PCI)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 16 May 2014
Price :
$35
*
At a glance
- Drugs Delparantag (Primary) ; Heparin
- Indications Blood coagulation disorders
- Focus Therapeutic Use
- Sponsors PolyMedix
- 16 May 2014 New trial record